Work toward potential treatments for COVID-19 is beginning to show tangible results at CSL Behring manufacturing facilities in Europe and Australia. CSL Behring is involved in multiple initiatives to address the pandemic with potential therapeutics, including efforts to produce hyperimmune serum, a treatment derived from the plasma of recovered COVID-19 patients that includes antibodies needed to fight the disease.
In late July, production got underway at our Broadmeadows, Australia, facility (above) on a COVID-19 Immunoglobulin-VF, a hyperimmune treatment that has the potential to treat hospitalized Australian patients with COVID-19, particularly those whose illness is progressing towards the need for ventilation.
The product manufactured here will be used in clinical trials to determine if the product is safe and effective in treating the novel coronavirus.
On the other side of the world in Bern, Switzerland, production of an investigational hyperimmune product (seen above) is already complete. Packaging of the treatment is taking place at CSL Behring’s Marburg, Germany, site. This effort is part of CSL Behring’s work with the CoVIg-19 Plasma Alliance, a collaboration between industry leaders that pools resources to develop a non-branded hyperimmune globulin that contains consistently high levels of antibodies to treat coronavirus.
A clinical trial to test the hyperimmune product in COVID-19 patients is set to begin in the coming weeks.
